Neos Therapeutics (NEOS) Misses Q4 EPS by 4c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. AMZN
2. INTC
3. PINS
4. COIN
5. RDDT
6. FSLR
7. FND
8. RIVN
9. SBUX
10. SNDK

Go back to Neos Therapeutics (NEOS) Misses Q4 EPS by 4c, Revenues Miss

Neos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results

March 13, 2020 7:46 AM EDT

Full year 2019 net revenues increased by 29% and operating loss decreased by $33M

 Neos RxConnect rapidly expanded with ~500 pharmacies in network at year-end

NT0502 Phase 1 ascending dose trial initiation planned in 2H20 following top-line PK data

Company to host conference call today at 8:30am ET

DALLAS and FORT WORTH, Texas, March 13, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today reported financial results for the fourth quarter and fiscal... More